Trade Margin Rationalisation on 137 Anti-Cancer Drugs

1. At a Glance

• What it is: NPPA has used Paragraph 19 of DPCO, 2013 to cap the trade margin at 30% of MRP on 137 non-scheduled anti-cancer drugs. These are drugs outside the ceiling-price list. [1]
• Expected effect: MRP to fall by up to 70%, depending on each drug's existing price structure. [1]
• Why it matters: It shows a second way of regulating drug prices. Instead of fixing a ceiling price (as for NLEM drugs), it limits the distribution and retail mark-up. It touches health access, out-of-pocket spending, the pharma industry and federal enforcement. [1][5]
• It scales up the 2019 pilot, which covered 42 drugs and 526 brands. [1][2]

2. Why in the News

• 17 Oct 2026: NPPA issued a Gazette notification capping trade margins on 137 anti-cancer drugs. Revised prices take effect from 9 Nov 2026. [1]
• The drug list was recommended by an Expert Committee under the DGHS. [1]
• Related 2024–26 measures on cancer drug costs:
• Customs duty cut to nil on three anti-cancer drugs. [9]
• Budget exemptions of Basic Customs Duty (BCD) on lifesaving drugs. [10][11]

3. Background & Evolution

• Rationale: Retail and distribution margins on non-scheduled anti-cancer drugs were excessive. Cancer patients carry a high financial burden. [1]
• 26 Feb 2019: NPPA used its extraordinary powers under Para 19, DPCO 2013 in public interest. It limited the trade margin on 42 non-scheduled anti-cancer medicines to up to 30% of the selling price (MRP). [3]
• 2019 pilot design: It was framed as a "proof of concept" TMR pilot. [2]
• Initial projection (Feb 2019): 72 formulations and 355 brands, with revised prices effective 8 Mar 2019. [3]
• Mar 2019: 390 brands (91% of the 426 brands reported by manufacturers) showed a price cut, of up to 87%. [4]
• Final pilot outcome:
• MRP of 526 brands reduced by up to 90%. [1][2]

• Later PIB releases cite an average cut of about 50% and patient savings of about ₹984 crore a year. An earlier release put the savings at about ₹1,000 crore. [2]

• COVID-19 period: The TMR mechanism was extended to five medical devices: pulse oximeter, BP monitor, nebulizer, digital thermometer and glucometer. [6]

• 2026: TMR was scaled up to 137 anti-cancer drugs. The list "would be updated periodically". [1]

4. Core Static Facts

• Key term – trade margin: the mark-up taken across the distribution and retail chain, here measured as a share of MRP. TMR limits this mark-up. It does not fix the drug's absolute price. [1]

5. Multi-Dimensional Analysis

Economic

• It targets margins in the distribution and retail channel "while safeguarding legitimate manufacturer revenues". [1]
• The 2019 pilot saved patients about ₹984 crore a year, which gives a benchmark for the larger 2026 round. [2]
• It works alongside fiscal measures:
• Nil customs duty and GST cut from 12% to 5% on Trastuzumab Deruxtecan, Osimertinib and Durvalumab. [9]
• Budget 2025-26: full BCD exemption on 36 lifesaving drugs. [10]

Social / Health equity

• It is meant to relieve patients and families facing very high cancer treatment costs, and supports equitable access to cancer care. [1]

Administrative

• Much of the supply of anti-cancer drugs goes directly to hospitals. Hospitals are therefore made responsible for charging revised prices and must show them on their websites. [1]
• Shared responsibility: NPPA (Centre) issues the order and State Drug Controllers enforce it. Health is a State subject, so this is a federal enforcement test. [1]
• Manufacturers must publish price lists on their websites and send them to retailers and hospitals. [1]

Legal / Regulatory

• Para 19 is the provision NPPA uses for extraordinary action. It has been used to cut prices (anti-cancer TMR, knee implants) and also to raise them: in 2024 the ceiling price of 11 formulations of 8 low-cost drugs was increased by 50% to keep them available. [3][7]

Market / Supply safeguards

• Companies must maintain current production and supply levels so that price cuts do not cause artificial shortages. [1]

Governance / Transparency

• Price display is required at pharmacies and on hospital websites, and consumers can check prices on Pharma Sahi Daam. This lowers the information gap for patients. [1]

6. Recent Developments (last 12–18 months)

• Feb 2025 (Budget 2025-26): BCD fully exempted on 36 lifesaving drugs for cancer, rare and chronic diseases; 6 others get a concessional 5% duty. [10]
• Feb 2026 (Budget 2026-27): BCD exempted on 17 drugs or medicines, particularly for cancer patients. [11]
• Mar 2026: PIB release on high trade margins in essential medical devices, recalling the TMR used for devices during COVID. [6]
• 17 Oct 2026: Gazette notification of TMR on 137 anti-cancer drugs. [1]
• 24 Oct 2026 (approx.): 7-day deadline for manufacturers to report revised prices, counted from the 17 Oct notification. [1]
• 9 Nov 2026: Revised prices take effect at retailers and hospitals. [1]

7. Prelims Hooks

• TMR on 137 anti-cancer drugs was notified by NPPA on 17 Oct 2026. [1]
• NPPA is under the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers. [1]
• Trade margin is capped at 30% of MRP. [1]
• Legal basis: Paragraph 19 of DPCO, 2013. [1]
• The drugs are non-scheduled, i.e. not in Schedule-I (NLEM). [1][5]
• The list was recommended by an Expert Committee under the DGHS. [1]
• Expected MRP cut: up to 70%. [1]
• Revised prices effective from 9 Nov 2026. [1]
• Manufacturers must report revised prices to NPPA within 7 days. [1]
• 2019 pilot: 42 drugs, 526 brands, MRP cut up to 90%. [1][2]
• The 2019 decision was taken at NPPA's meeting of 26 Feb 2019. [3]
• Consumers can check prices on the Pharma Sahi Daam app. [1]
• Compliance is enforced by State Drug Controllers. [1]
• NLEM 2022 has 384 medicines and forms Schedule-I of DPCO 2013. [5][8]
• GST on Trastuzumab Deruxtecan, Osimertinib and Durvalumab was cut from 12% to 5%, and their customs duty to nil. [9]

8. Why a Cap on the Margin Is Not a Cap on the Price

• The rule cuts the shop's share, not the company's price
• TMR (Trade Margin Rationalisation, a limit on the extra amount distributors and sellers add) caps that extra amount at 30% of MRP (Maximum Retail Price, the highest price printed on the pack) [1].
• The manufacturer's own selling price is left alone. PIB says the rule protects "legitimate manufacturer revenues" [1].

• So if a company already sells a drug to the trade at a very high price, the MRP stays high even after the cap.

• "Up to 70%" is the best case, not the usual case

• PIB says the cut will vary with each drug's existing price structure [1].
• In the 2019 pilot, the headline said "up to 90%", but the average cut was about 50% [2].

• In an answer, quote the average along with the maximum.

• The launch price problem stays outside the rule

• The Parliamentary Standing Committee found gaps in how drugs are classified. These gaps let companies launch non-scheduled drugs (drugs with no government ceiling price) at unjustified starting prices [12].
• TMR only acts on the margin added after the company's price. It does not ask whether the company's price is fair.

9. Seven Years On, Still Running on Emergency Powers

• The tool is still a one-off order, not a standing rule
• In 2019 and again in 2026, TMR was imposed under Para 19 of DPCO 2013. Para 19 is an extraordinary power for use in the public interest [1][3].

• In August 2026 the Standing Committee noted that there is still no timeline for making TMR a permanent part of DPCO 2013 [12].

• Why this matters

• An emergency power depends on a fresh decision each time, made case by case.
• Para 19 has been used both to cut prices and to raise them (8 drugs in 2024) [7]. So the power has no fixed direction, and no fixed formula for which drugs qualify.

• The 137-drug list "would be updated periodically" [1], but no rule says how often, or on what test.

• What a permanent rule would change

• A margin cap written into DPCO would apply to every drug that qualifies, automatically.
• Today it covers only the drugs an expert committee picks [1].

10. Why Catching Overcharging Has Not Worked So Far

• NPPA's record on recovering money is weak
• When a company charges above a notified price, NPPA sends a demand notice asking it to pay back the excess [12].
• As of 2025, ₹8,526 crore, or 85% of the total amount demanded, had not been recovered [12].

• About 70% of that money is stuck in court cases, some pending for over 20 years [12].

• What this means for TMR

• Punishing overcharging after it happens does not bring money back to patients in time.

• So TMR works only if wrong prices are stopped at the counter, before the sale.

• Hospitals are the hardest counter to watch

• Many anti-cancer drugs go straight to hospitals, so hospitals must charge the revised price and show it on their websites [1].
• Checks fall to State Drug Controllers [1], while the order itself comes from the Centre. A State that does little checking leaves the central order on paper only.
• A patient on a hospital bill usually cannot check each drug price against Pharma Sahi Daam [1] while treatment is going on.

11. The Supply Worry — and Why It Is Only Partly Right

• The strongest objection
• If prices fall too far, some brands may stop being worth selling. Companies or dealers could then cut supply, leaving patients with no drug at all.

• This is not just theory. In 2024 NPPA used Para 19 to raise ceiling prices of 8 low-cost drugs by 50% so that they would stay available [7].

• The answer

• TMR is aimed at the trade margin, not the maker's price [1]. The company's income per pack should therefore change much less than the MRP does.
• The 2026 order directly tells companies to keep production and supply at current levels [1].

• In 2019, NPPA tracked the effect brand by brand: 390 of 426 reported brands showed a cut by March 2019 [4].

• What is fair in the objection

• The PIB releases report price cuts, not whether stock reached pharmacies and hospitals afterwards [2][4].
• So the supply risk has not been disproved, only left untested. It needs to be checked with real availability data after 9 Nov 2026.

12. What Parliament Has Asked the Government to Do Next

• Department of Pharmaceuticals: make TMR permanent in DPCO 2013
• The Standing Committee on Chemicals and Fertilizers flagged that the pilot has no timeline for becoming a permanent framework [12].

• A permanent rule would end the drug-by-drug use of emergency power.

• NPPA: set up a dedicated legal cell and a fast-track route for disputes

• The Committee recommended both to clear old overcharging cases [12].

• Without this, money demanded for violations of the new 30% cap could join the ₹8,526 crore backlog [12].

• Department of Pharmaceuticals: review how drugs are classified

• The Committee asked for this to stop unjustified launch prices for non-scheduled drugs [12].

• This closes the gap TMR leaves open: the manufacturer's own price.

• NPPA: publish what happened after the cut, not just the cut

• In 2019, NPPA released brand-level compliance figures within weeks [4].
• Repeating this for 2026, and adding supply data for hospitals, would show whether patients actually got the cheaper drug.

13. Anchors for Answers

• Data: The 2019 TMR pilot cut MRP by about 50% on average across 526 brands and saved patients about ₹984 crore a year [2]
• Data: ₹8,526 crore (85%) of the amount NPPA demanded for overcharging was unrecovered as of 2025; about 70% of it is in litigation [12]
• Report/Committee: Standing Committee on Chemicals and Fertilizers (Chair: Azad Kirti Jha), 33rd Report (2025-26), Review of Role, Functions and Duties of NPPA, presented 6 Aug 2026. It found no timeline for a permanent TMR framework in DPCO [12][13]
• Law/Case: Paragraph 19, Drugs (Prices Control) Order 2013, NPPA's extraordinary power in public interest, used both to cut prices (TMR) and to raise them (2024) [1][7]
• Scheme: Pharma Sahi Daam app, which lets patients check the notified price of a drug [1]

14. Mains Relevance

• GS-II: Health; government policies and interventions; issues in social-sector services; Centre–State relations in implementation.
• GS-III: Industrial policy (pharmaceuticals); effects of price regulation on markets.
• GS-IV (marginal): Ethics in business, i.e. profiteering on life-saving drugs.
• Possible question stems: 1. Trade Margin Rationalisation offers a market-friendly alternative to ceiling-price control in India's drug pricing. Critically examine with reference to anti-cancer medicines. (250 words) 2. Lowering cancer drug prices alone cannot ensure access. Discuss the role of pricing, fiscal and supply-side measures in reducing out-of-pocket expenditure on cancer care. (250 words) 3. Discuss the challenges of enforcing central drug-price notifications through State machinery, especially where hospitals are major suppliers of medicines. (150 words)

15. Related Topics to Study Next

• DPCO 2013 and NLEM 2022: the ceiling-price regime that TMR complements. [5][8]
• NPPA's Para 19 powers: used both for price cuts and price increases. [7]
• TMR on medical devices during COVID-19: the same tool applied outside drugs. [6]
• Customs and GST relief on cancer drugs (2024–26): the fiscal route to affordability. [9][10][11]
• Pharma Sahi Daam and consumer redressal: price transparency tools. [1]
• Statutory basis of DPCO (Essential Commodities Act) and the role of DGHS/CDSCO: not verified in this note's sources; check on indiacode.nic.in.
• Out-of-pocket health expenditure and AB-PMJAY: the wider affordability context (not sourced here).

16. NCERT Concepts to Revise

• Price control (Economy): TMR and ceiling prices are two ways the government regulates drug prices; this is the core idea.
• Maximum Retail Price (Economy): The 30% trade margin cap is calculated on MRP, and the expected cut is in MRP.
• Essential commodities (Economy): DPCO rests on the state's power to control supply and prices of essential goods like medicines.
• Centre-state relations (Polity): The Centre's NPPA order depends on State Drug Controllers for enforcement, since health is a State subject.
• Standing committee (Polity): A parliamentary Standing Committee reviewed NPPA and asked for TMR to become permanent and for recovery of overcharged money.
• Supply (Economy): Price cuts risk shortages, so companies must maintain supply; explains the supply-side objection.

17. Common Errors / Trap Areas

• Wrong ministry: NPPA is under the Ministry of Chemicals & Fertilizers (Dept. of Pharmaceuticals), not the Ministry of Health. The DGHS (Health) only recommended the list. [1]
• Scheduled vs non-scheduled: TMR covers non-scheduled drugs. Scheduled (NLEM/Schedule-I) drugs get ceiling prices. [1][5]
• Mixing up the numbers:
• 2019: 42 drugs, 526 brands, cut up to 90%. [2]
• 2026: 137 drugs, cut up to 70%. [1]

• Also: 390 brands / up to 87% was an interim March 2019 figure; 63 is the number of anti-cancer drugs in NLEM. [4][5]

• Base of the cap: the 30% cap is calculated on MRP, not on cost or on the price to the distributor. [1]

• Key dates: notified 17 Oct, effective 9 Nov 2026. The 2019 pilot's prices took effect on 8 Mar 2019. [1][3]